Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07133633 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
A Phase 2 study of Radiographic Axial Spondyloarthritis, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 315
- Enrollment target
- 20
- Study locations
NCT07133633: Recruiting Phase 2 study of Radiographic Axial Spondyloarthritis, sponsored by Merck Sharp & Dohme.
NCT07133633 is a Phase 2 study of Radiographic Axial Spondyloarthritis that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 315 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (137% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07133633, a Phase 2 study of Radiographic Axial Spondyloarthritis, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 315 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat radiographic axial spondyloarthritis (r-axSpA). R-axSpA is a type of arthritis that causes pain, stiffness, and inflammation (swelling) in the spine and joints in the pelvis (hip bone). Radiographic means the damage it causes can be seen on X-rays. This study will help find out if a study medicine called tulisokibart can treat symptoms of r-axSpA. Researchers will look at different doses of tulisokibart. Researchers want to know if at least one of the study doses of tulisokibart works better than a placebo to improve r-axSpA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
Primary Outcome
ASAS 40 is defined as a relative improvement of ≥40% and an absolute improvement of ≥2 units from baseline in ≥3 of 4 domains, with no deterioration in the fourth domain. The 4 domains include Patient Global Assessment (PtGA), total spinal pain, physical function, and morning stiffness. Each domain is measured on a 10-point numeric scale from 0 = no disease symptoms/impact to 10 = extreme disease symptoms/impact, with a higher score indicating more severe impairment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tulisokibart
Study Locations (20)
Arizona
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler ( Site 0036) - Chandler
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff ( Site 0021) - Flagstaff
- Arizona Arthritis & Rheumatology Associates, P.C. - Gilbert ( Site 0022) - Gilbert
- AARA Arizona Arthritis & Rheumatology Associates, P.C. - Glendale ( Site 0056) - Glendale
- Arizona Arthritis & Rheumatology Associates, P.C. - Tucson ( Site 0025) - Tucson
California
- TriWest Research Associates - Chula Vista ( Site 0013) - Chula Vista
- Newport Huntington Medical Group ( Site 0005) - Huntington Beach
- Cohen Medical Centers ( Site 0034) - Thousand Oaks
- Inland Rheumatology Clinical Trials, Inc. ( Site 0002) - Upland
Florida
- Arthritis and Rheumatic Disease Specialties ( Site 0016) - Aventura
- Bay Area Arthritis and Osteoporosis ( Site 0041) - Brandon
- GNP Research - Hollywood ( Site 0020) - Cooper City
- Innovation Medical Research Center ( Site 0012) - Palmetto Bay
Illinois
- Chicago Arthritis & Regenerative Medicine ( Site 0042) - Chicago
- Willow Rheumatology and Wellness, PLLC ( Site 0035) - Willowbrook
Missouri
- Kansas City Physician Partners ( Site 0027) - Kansas City
- Velocity Clinical Research - West County Rheumatology, St. Louis ( Site 0038) - St Louis
Maryland
- Arthritis and Rheumatism Associates - Rockville ( Site 0019) - Rockville
Nebraska
- Physician Research Collaboration, LLC ( Site 0057) - Lincoln
New Mexico
- Inspire Santa Fe Medical Group ( Site 0011) - Santa Fe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2025-09-26 |
| Est. Completion | 2030-02-05 |
| Phase | Phase 2 |
What NCT07133633 shows while recruiting
NCT07133633 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (137% higher).
The record links to 1 condition, with Radiographic Axial Spondyloarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07133633 names 20 study sites across 8 states, led by Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07133633 about?
NCT07133633 is a clinical study titled "A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)". Researchers are looking for new ways to treat radiographic axial spondyloarthritis (r-axSpA). R-axSpA is a type of arthritis that causes pain, stiffness, and inflammation (swelling) in the spine and joints in the pelvis (hip bone). Radiographic means the damage it causes can be seen on X-rays. This...
What is the current status of trial NCT07133633?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 315 participants. The study started on 2025-09-26. Estimated completion is 2030-02-05.
What conditions does trial NCT07133633 study?
This clinical trial studies the following conditions: Radiographic Axial Spondyloarthritis.
What interventions are being tested in trial NCT07133633?
The interventions under investigation include: Placebo (DRUG), Tulisokibart (DRUG).
Who is sponsoring clinical trial NCT07133633?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07133633 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07133633's enrollment target sits among peer trials
315 157th of 2000 higher than 1,842 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI